Clinical Trials · NCT04074317

Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D

Name: Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 2Pramlintide

Phase: Phase 2
Recruitment status: Completed
Sponsor: Xeris Pharmaceuticals
Enrollment: 18
Start date: Aug 2019
Locations: 1 site, United States
Primary endpoint: Area Under the Curve 0-180 Minutes for Plasma Glucose >180 mg/dL

View Pramlintide compound reference